Φορτώνει......
Fragile X targeted pharmacotherapy: lessons learned and future directions
Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Neurodev Disord |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467059/ https://ncbi.nlm.nih.gov/pubmed/28616096 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-017-9186-9 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|